102 related articles for article (PubMed ID: 34181497)
1. Healthcare costs of patients with cancer stratified by Khorana score risk levels.
Khorana AA; Kuderer NM; McCrae K; Milentijevic D; Germain G; Laliberté F; MacKnight SD; Lefebvre P; Lyman GH; Streiff MB
J Med Econ; 2021; 24(1):866-873. PubMed ID: 34181497
[TBL] [Abstract][Full Text] [Related]
2. Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels.
Khorana AA; Kuderer NM; McCrae K; Milentijevic D; Germain G; Laliberté F; MacKnight SD; Lefebvre P; Lyman GH; Streiff MB
Cancer Med; 2020 Nov; 9(21):8062-8073. PubMed ID: 32954653
[TBL] [Abstract][Full Text] [Related]
3. All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries.
Lefebvre P; Laliberté F; Nutescu EA; Duh MS; LaMori J; Bookhart BK; Olson WH; Dea K; Schein J; Kaatz S
J Manag Care Pharm; 2012 Jun; 18(5):363-74. PubMed ID: 22663169
[TBL] [Abstract][Full Text] [Related]
4. Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants.
Streiff M; Milentijevic D; McCrae KR; Laliberté F; Lejeune D; Lefebvre P; Schein J; Khorana AA
J Med Econ; 2019 Nov; 22(11):1134-1140. PubMed ID: 31106638
[No Abstract] [Full Text] [Related]
5. Comparison between the Khorana prediction score and Caprini risk assessment models for assessing the risk of venous thromboembolism in hospitalized patients with cancer: a retrospective case control study.
Hu Y; Li X; Zhou H; Lin P; Zhang J; Huang D; Qi M; Tang Y; Yi Q; Liang Z; Wang M
Interact Cardiovasc Thorac Surg; 2020 Oct; 31(4):454-460. PubMed ID: 32910201
[TBL] [Abstract][Full Text] [Related]
6. Healthcare resource utilization and costs associated with venous thromboembolism recurrence in patients with cancer.
Khorana AA; McCrae KR; Milentijevic D; Laliberté F; Lejeune D; Crivera C; Lefebvre P
J Med Econ; 2020 Apr; 23(4):323-329. PubMed ID: 31818164
[No Abstract] [Full Text] [Related]
7. Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population.
Hlavacek P; Guo JD; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R
Curr Med Res Opin; 2019 Dec; 35(12):2043-2051. PubMed ID: 31387467
[No Abstract] [Full Text] [Related]
8. Validation of the Khorana Score for Prediction of Venous Thromboembolism After Robot-Assisted Radical Cystectomy.
Iqbal U; Elsayed AS; Ozair S; Jing Z; James G; Li Q; Hussein AA; Guru KA
J Endourol; 2021 Jun; 35(6):821-827. PubMed ID: 33218263
[No Abstract] [Full Text] [Related]
9. Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors.
Lin HM; Pan X; Hou P; Huang H; Wu Y; Ren K; Jahanzeb M
J Med Econ; 2020 Aug; 23(8):894-901. PubMed ID: 32347754
[No Abstract] [Full Text] [Related]
10. Healthcare costs of NVAF patients treated with rivaroxaban and apixaban in the US.
Milentijevic D; Germain G; Laliberté F; Bookhart BK; MacKnight SD; Tsang J; Lefebvre P
J Med Econ; 2020 Nov; 23(11):1365-1374. PubMed ID: 32897766
[TBL] [Abstract][Full Text] [Related]
11. Validation of the Khorana Score to Assess Venous Thromboembolism and Its Association with Mortality in Cancer Patients: A Retrospective Community-based Observational Experience.
Ahmed G; Nasir HG; Hall K; Weissmann L
Cureus; 2020 Apr; 12(4):e7883. PubMed ID: 32489737
[TBL] [Abstract][Full Text] [Related]
12. Predicting risk of venous thromboembolism in hospitalized cancer patients: Utility of a risk assessment tool.
Patell R; Rybicki L; McCrae KR; Khorana AA
Am J Hematol; 2017 Jun; 92(6):501-507. PubMed ID: 28240823
[TBL] [Abstract][Full Text] [Related]
13. Frequency of hospital readmissions for venous thromboembolism and associated hospital costs and length of stay among acute medically ill patients in the US.
Amin A; Deitelzweig S; Bucior I; Lin J; Lingohr-Smith M; Menges B; Neuman WR
J Med Econ; 2019 Nov; 22(11):1119-1125. PubMed ID: 31084383
[No Abstract] [Full Text] [Related]
14. Costs of venous thromboembolism associated with hospitalization for medical illness.
Cohoon KP; Leibson CL; Ransom JE; Ashrani AA; Petterson TM; Long KH; Bailey KR; Heit JA
Am J Manag Care; 2015 Apr; 21(4):e255-63. PubMed ID: 26244788
[TBL] [Abstract][Full Text] [Related]
15. Real-world comparison of hospitalization costs for heart failure in type 2 diabetes mellitus patients with established cardiovascular disease treated with canagliflozin versus other antihyperglycemic agents.
Chen YW; Voelker J; Tunceli O; Pericone CD; Bookhart B; Durkin M
J Med Econ; 2020 Apr; 23(4):401-406. PubMed ID: 31801393
[No Abstract] [Full Text] [Related]
16. Phase-specific and lifetime economic burden of cervical cancer and endometrial cancer in a commercially insured United States population.
Shah R; Corman S; Shah A; Kebede N; Nwankwo C
J Med Econ; 2021; 24(1):1221-1230. PubMed ID: 34686073
[TBL] [Abstract][Full Text] [Related]
17. Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.
Vekeman F; LaMori JC; Laliberté F; Nutescu E; Duh MS; Bookhart BK; Schein J; Dea K; Olson WH; Lefebvre P
J Med Econ; 2011; 14(3):324-34. PubMed ID: 21506632
[TBL] [Abstract][Full Text] [Related]
18. Incidence of venous thromboembolism and discriminating capacity of Khorana score in lung cancer patients treated with immune checkpoint inhibitors.
Alma S; Eloi D; Léa V; Julie C; Valérie M; Pierre G; Hilgers W; Philippe G; Christine Z; Philippe D
J Thromb Thrombolysis; 2022 Aug; 54(2):287-294. PubMed ID: 35396660
[TBL] [Abstract][Full Text] [Related]
19. Assessing hypercoagulability and VTE risk using thromboelastography and Khorana score in women with cancers receiving chemotherapy.
Tera Y; Suh YJ; Fainchtein K; Agrawal A; Mates M; Othman M
Am J Hematol; 2024 Apr; 99 Suppl 1():S19-S27. PubMed ID: 38425173
[TBL] [Abstract][Full Text] [Related]
20. Healthcare costs associated with rivaroxaban or warfarin use for the treatment of venous thromboembolism.
Coleman CI; Baugh C; Crivera C; Milentijevic D; Wang SW; Lu L; Nelson WW
J Med Econ; 2017 Feb; 20(2):200-203. PubMed ID: 27780397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
